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Abstract
Purpose: Leiomyosarcoma of the urinary bladder is exceed-
ingly rare. Most clinicians come across only a few cases dur-
ing their career, and information regarding treatment and 
outcome is scattered in the scientific literature. Interested 
clinicians and patients have to undertake troublesome 
search for treatment and outcome information. Material 
and methods: We performed a systematic review of the lit-
erature using the PubMed and Web of Science databases 
and included all identified cases published in English lan-
guage between 1970 and June 2018 into a meta-analysis. 
Prior to the literature search, key questions were formulated 
and with the data obtained, answers to these questions 
should be derived. Results: We analyzed clinical data of 210 
cases of urinary bladder leiomyosarcoma revealed by this re-
view and seen in our institution. The mean age of patients 
was 52 years. The majority (75%) of the tumors was classified 
as high-grade sarcomas. We found no report of a prior radia-
tion therapy to the pelvic organs, but some authors suggest-
ed an association between cyclophosphamide treatment 
and the development of bladder leiomyosarcoma, especial-
ly in patients with retinoblastoma. For the whole sample, we 
determined 5- and 10-year cancer-specific cumulative mor-
tality rates of 38 and 50%. Patients with high-grade sarcomas 
had a trend toward a higher mortality compared with low-
grade tumors (p = 0.0280). The most promising treatment 
option seems to be surgery (radical or partial cystectomy) 
with negative resection margins, possibly supplemented by 
chemotherapy or radiation. Conclusion: About half of pa-
tients with bladder leiomyosarcoma survived on the long 
run. Low-grade tumors may have a better outcome with, 
nevertheless, countable long-term mortality. For better as-
sessment of that rare bladder tumor, its best treatment op-
tions, and the influence of neoadjuvant or adjuvant thera-
pies on the outcome of patients, a larger series with long-
term survival data is required. © 2018 S. Karger AG, Basel
Introduction
Non-urothelial neoplasms rarely occur in the urinary 
bladder. Leiomyosarcoma represents the most common 
subtype of malignant mesenchymal tumors in this organ 
but still accounts for less than 1% of all primary bladder 
tumors [1]. Until now, knowledge about this rare disease 
Leiomyosarcoma of the Urinary Bladder 
in Adult Patients: A Systematic Review
97Urol Int 2019;102:96–101
DOI: 10.1159/000494357
comes mainly from individual case reports or smaller 
case series and there is only little information about 
long-term survival rates. The largest series published 
was a Surveillance, Epidemiology, and End Results data-
base study enrolling 183 patients treated between 1973 
and 2010 [1]. In our study, we performed a systematic 
review of the literature with meta-analysis of reported 
cases with sufficient data in order to give clinicians and 
patients a rapid overview on the knowledge about this 
rare disease.
Material and Methods
The PubMed and Web of Science databases were used to per-
form a systematic literature review, based on the criteria described 
by Galfano and Novara [2]. With the key words “leiomyosarcoma” 
and “bladder,” 386 articles could be retrieved on the PubMed and 
232 items on the Web of Science database on June 8, 2018. We only 
considered articles in English language that were published be-
tween 1970 and June 2018. Patients with a primary urinary bladder 
leiomyosarcoma and a minimum age of 16 years were included. 
We identified 209 published cases and added 1 unpublished case 
seen in our institution. Detailed characteristics about all these cas-
es are summarized in an online supplementary Table (see www.
karger.com/doi/10.1159/000494357) [3–81]. In some larger series, 
it was not possible to assign clinical information to each patient [1, 
57, 60, 82]. However, when survival details were given for indi-
vidual cases [57, 60], they were included into the statistical analy-
sis. 
The follow-up information of 2 patients seen in our clinic and 
published earlier [39] was updated. The following key questions 
were formulated prior to literature search in order to be an-
swered with the data obtained by this review: (1) predisposing 
factors for the development of bladder leiomyosarcomas; (2) 
mean age of patients at the time of diagnosis; (3) proportion of 
primary surgical treatment; (4) sites and time of tumor recur-
rence; (5) 5- and 10-year cumulative mortality rates of high-
grade versus low-grade tumors. The statistical analysis was per-
formed with the Statistical Analysis Systems (SAS Institute Inc., 
Cary, NC, USA), using competing risk analyses to determine cu-
mulative disease-specific mortality rates and Pepe-Mori tests to 
compare the mortality curves. All stated percentages are based 
on the number of articles with existent information about the 
specific topics, articles with unknown information were not con-
sidered. 
Results 
Overall, 210 cases with data suitable for statistical 
analysis were identified. Fifty-eight percent of the tu-
mors occurred in males. Age at diagnosis ranged from 
16 to 88 years, with a mean age of 52 years. Data on 
symptoms were available in 91 out of 210 cases (43%). 
Painless hematuria was the most frequently reported 
symptom (80%), less common symptoms included dys-
uria, nocturia, obstructive symptoms, increased fre-
quency of micturition, pelvic and abdominal pain, uri-
nary retention, or recurrent urinary tract infections. 
The sarcomas had a mean size of 6 cm (range 0.5–16 
cm) and 75% were classified as high-grade tumors. 
None of the patients had a history of radiation therapy 
of the pelvic organs, but there were 7 cases with radia-
tion of the head and neck region for Hodgkin’s or non-
Hodgkin’s lymphomas and retinoblastomas. Fourteen 
patients were affected by retinoblastoma in childhood; 
9 of them had received a chemotherapy including cyclo-
phosphamide. Altogether, 5 patients had a cyclophos-
phamide therapy for other diseases. Further, the occur-
rence of bladder leiomyosarcomas was described for 1 
patient with schistosomiasis, 1 with a long-term tamox-
ifen therapy and 1 with chronic ketamine abuse. Metas-
tases were mentioned only in 4 cases (2%) at the time of 
diagnosis, twice in the lymph nodes and twice with un-
known site. 
Seventy-eight percent (n = 120) of the patients with 
information about therapy (n = 153) underwent pri-
marily surgical treatment (radical cystectomy in 66/153 
[43%], partial cystectomy in 54 cases [35%]). Out of 
these 120 patients, 31 (26%) received a neoadjuvant or 
adjuvant radiation or chemotherapy in addition to sur-
gery. A total of 26 patients had a transurethral resection 
of the bladder tumor only with no further reported sur-
gical procedure. Chemotherapy or radiation was the 
only treatment for 9 patients. In 55 cases, complete resec-
tion with negative surgical margin status was reported. 
Tumor recurrence was observed in 53 out of 210 patients 
(25%), predominantly locally in the pelvis (18/53 recur-
rences, 34%) and within the first 3 years after therapy. 
Distant metastases were mainly located in the lung, liver, 
or bones. Only 2 late recurrences were reported (8 and 
12 years after diagnosis, respectively [31, 53]). The lon-
gest documented follow-ups of bladder leiomyosarcoma 
patients were 20 years after a radical cystectomy [22] and 
narrowly 22 years after a partial cystectomy ([39], up-
dated follow-up). Disease-specific cumulative mortality 
rate was 18% after 1 year, 38% after 5 years, and 50% af-
ter 10 years for all leiomyosarcoma patients (Fig. 1; Table 
1). Compared with patients with high-grade tumors (n = 
95), those with low-grade tumors (n = 32) had a lower 
mortality rate (Fig. 2; Table 1). Disease-specific cumula-
tive mortality rates were 58 and 69% after 5 and 10 years 
for high-grade sarcomas, 7 and 27% for low-grade sarco-
mas. 
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Discussion
With this systematic literature review of all reported 
cases of urinary bladder leiomyosarcomas since 1970, we 
were able to analyze the clinical features and survival data 
of 209 published case reports and 1 added unpublished 
case seen at our department. It has to be considered that 
the extent of information varied among the articles and 
completeness of data could not be achieved. Only the 127 
cases with information about tumor grading could be 
used for the statistical comparison of high-grade and low-
grade sarcomas (Fig.  2). Repeatedly, an association be-
tween cyclophosphamide treatment and the develop-
ment of bladder leiomyosarcoma was observed (14 cases). 
It has been hypothesized that such treatment especially in 
patients with a genetic retinoblastoma could be a risk fac-
tor for this rare bladder tumor [83]. We did not find a case 
with a prior radiation to the pelvic organs, but to the head 
and neck region for lymphomas and retinoblastomas sug-
gesting that local radiotherapy plays no major role in the 
pathogenesis of bladder leiomyosarcoma. A schistosomi-
asis of the urinary bladder as a documented risk factor for 
the development of bladder tumors was observed in 1 pa-
tient [20, 84]. The reviewed sarcomas were diagnosed at 
a median age of 52 years, with a male to female ratio of 
1.4: 1. The frequently used primary treatment was sur-
gery, with radical cystectomy being the most common 
procedure, followed by partial cystectomy, which can be 
adequate for smaller tumors. Spiess et al. [85] reported a 
series of 19 bladder sarcoma patients (mainly leiomyosar-
comas) and showed an association between the surgical 
margin status and the recurrence-free, disease-specific 
and overall survival. They revealed a 5-year disease-spe-
cific survival rate of 59%, which is very close to our results 
[85]. In our study, we determined 5- and 10-year disease-
specific cumulative mortality rates of 38 and 50% for all 
reviewed bladder leiomyosarcoma patients, 58 and 69% 
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Fig. 1. Cumulative disease-specific mortality rate in the whole 
sample of tumors with follow-up data allowing meta-analysis (n = 
210).
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Fig. 2. Cumulative disease-specific mortality rate of high-grade 
(n = 95) vs. low-grade tumors (n = 32), p = 0.0280. Grading was 
not available in 83 cases.
Table 1. Disease-specific cumulative mortality rates for the whole 
sample and separately for low-grade versus high-grade leiomyo-
sarcoma patients after 1, 5 and 10 years with 95% CI and numbers 
of patients at risk at these time points. Data obtained by system-
atic review of the literature
Time Patients at 
risk, n
Cumulative 
disease-specific 
mortality rate, %
95% CI
All patients
1 year 109 18 12–24
5 years 35 38 29–48
10 years 7 50 37–64
Low-grade
1 year 20 0 Not available
5 years 9 7 0–20
10 years 2 27 6–57
High-grade
1 year 40 33 22–44
5 years 12 58 44–72
10 years 2 69 50–89
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for patients with a high-grade sarcoma, and 7 and 27% for 
low-grade tumors. Rosser et al. [82] documented a 5-year 
disease-specific survival rate of 62% in a series of 36 high-
grade bladder leiomyosarcomas that were mainly treated 
with radical cystectomy, frequently combined with neo-
adjuvant or adjuvant chemotherapy. Doxorubicin and if-
osfamide were the most commonly used regimens. The 
authors described downstaging in all 4 patients with met-
astatic disease that received neoadjuvant chemotherapy 
[82]. We did not identify a case of complete response 
achieved by chemotherapy alone, but in 1 case treated by 
radiation following chemotherapy for a low-grade leio-
myosarcoma [68], suggesting that multimodal treatment 
could be beneficial in individual cases of advanced dis-
ease. Rodríguez et al. [1] published the largest series of 
bladder leiomyosarcoma patients so far. They reported 
5- and 10-year cancer-specific survival rates of 47 and 
35% for 183 patients detected with the Surveillance, Epi-
demiology and End Results database. Moreover, they 
showed that an undifferentiated tumor grade, distant dis-
ease, and the absence of surgical treatment were associ-
ated with a worse outcome [1]. In comparison to our 
study, they revealed lower cancer-specific survival rates, 
which may be caused by a higher median age of patients 
(65 vs. 52 years) or the higher proportion of distant dis-
ease at the time of diagnosis (10 vs. 2%). A total of 25% of 
the patients in our meta-analysis experienced a tumor re-
lapse, which mainly occurred in the pelvis as a local recur-
rence and within the first 3 years after primary treatment. 
The lung, liver and bones were common sites for distant 
metastases. Diagnostic workup should focus on these 
sites. 
This study has several limitations. The information 
that was obtained from the analyzed case series and single 
case reports was partially incomplete and the follow-up 
was limited. It may not be ruled out that there was some 
publication bias with a preferred reporting of unusual 
cases and/or cases with apparently successful treatment. 
Because of the long time period considered with the lit-
erature search, it is conceivable that current classification 
standards would change the histopathological classifica-
tion of some tumors. 
Conclusion
Leiomyosarcoma of the urinary bladder commonly 
presents as a high-grade tumor. We determined 5- and 
10-year cancer-specific cumulative mortality rates of 38 
and 50% in this systematic review and meta-analysis of 
210 cases. The most important treatment option seems to 
be surgical resection (radical or partial cystectomy) with 
negative margins. Surgery can be supplemented by che-
motherapy or radiation, especially for metastatic disease 
or to achieve resectability.
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